หมวดหมู่: CISION PR Newswire – English Feeds
-
Solas Fiduciary Services expands further in Dubai
SINGAPORE, Dec. 3, 2025 /PRNewswire/ — Solas Fiduciary…
-
DNAKE Donates Smart IP Intercom Systems to Habitat for Humanity Greater Los Angeles, Strengthening Home Security for Local Families
LOS ANGELES, Dec. 3, 2025 /PRNewswire/ — DNAKE, a lead…
-
Beep Receives Frost & Sullivan’s 2025 North American Technology Innovation Leadership Recognition for Excellence in Scalable, Service-Oriented Autonomous Mobility Solutions
Beep is honored for combining innovation, operational e…
-
RSYC Lights Up Singapore’s West Coast With The Nation’s Most Illuminated Christmas Boat Parade
SINGAPORE, Dec. 3, 2025 /PRNewswire/ — The Republic of…
-
EPG Earns Malaysia’s BOMBA Approval, Paving the Way for Wider Modular Data Center Deployment in ASEAN
SINGAPORE, Dec. 3, 2025 /PRNewswire/ — EPG, a leading …
-
Hyundai Motor Group Unveils Production-Ready Autonomous Mobility Robot Platform ‘MobED’ at iREX 2025
MobED, Hyundai Motor Group Robotics LAB’s first mass-pr…
-
foodpanda expands ‘panda hearts’ programme, reports 30% drop in rider accidents across Asia
SINGAPORE, Dec. 3, 2025 /PRNewswire/ — foodpanda has a…
-
Simplifying cross-border business: Statrys expands in Singapore with a unified CAB platform for SMEs
SINGAPORE and HONG KONG , Dec. 3, 2025 /PRNewswire/ — …
-
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
SINGAPORE, Dec. 3, 2025 /PRNewswire/ — MediThinQ, a fa…
-
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL …